Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Nous-209 has been developed using the Nouscom's viral vector platform
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
New agreement applies to the polymers of the Medical Care series portfolio
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated